The Maine Cancer Genomics Initiative (MCGI), a clinical research group within the Jackson Laboratory, is leading an alliance of clinical oncologists in Maine to expand education, clinical trial access, and treatment options for oncologists across rural and underserved areas. The initiative aims to reduce disparities in access to precision medicine, a critical need in cancer care.
Genomic Tumor Boards and Cancer Care Delivery
In collaboration with Columbia University, MCGI is currently studying the impact of structured Genomic Tumor Boards (GTBs) on cancer care delivery in community oncology practices through a nationwide study (S2108CD). This project involves collecting study data and building a structured database for over 1,000 enrolled patients, forming a basis for data analyses. The research seeks to understand how GTBs can optimize treatment decisions and improve patient outcomes in diverse settings.
HER2 Expression and Treatment Implications
Another research project at MCGI focuses on the HER2 protein, which plays a significant role in cell proliferation. Evaluating HER2 expression and activation is crucial in treating several cancer types. The work involves analyzing HER2 results for patients enrolled in the MCGI2.0 study to better understand the expanding treatment implications of HER2. This analysis aims to refine treatment strategies based on HER2 status, potentially leading to more effective and personalized therapies.
Addressing Healthcare Disparities
This initiative highlights the critical importance of collaborative networks in addressing healthcare disparities in rural and underserved areas. By focusing on precision medicine and expanding access to clinical trials and advanced treatments, MCGI is working to improve cancer care delivery and outcomes for all patients.
